Alnylam picks Agilent to make API for lead RNAi candidate

By Dan Stanton

- Last updated on GMT

GettyImages/TimArbaev
GettyImages/TimArbaev
Agilent Technologies will make the commercial drug substance for Alnylam and Sanofi’s investigational RNA interference (RNAi) therapeutic patisiran.

Alnylam Pharmaceuticals noted in an SEC filing​ it has entered into a five-year manufacturing services agreement for commercial supply of patisiran drug substance with Agilent.

“Agilent has agreed to manufacture and supply to the Company [Alnylam], and the Company has agreed to purchase from Agilent… a specified percentage of the active pharmaceutical ingredients [APIs] required for patisiran for commercial sale,”​ Alnylam said.

Alnylam will be required to provide an initial payment to cover raw material purchases and reserve appropriate resources, though figures were not disclosed.

Technology and manufacturing firm Agilent has a 69,000 sq ft GMP commercial API facility located in Boulder, Colorado.

Patisiran (ALN-TTR02), an intravenously administered RNAi therapeutic to treat the inherited disease Transthyretin (TTR)-mediated amyloidosis, is Alnylam’s lead therapy and is being developed in a $700m alliance with Sanofi’s Genzyme division inked in 2014​.

Designed to target and silence specific messenger RNA, potentially blocking the production of TTR protein before it is made, the Phase III therapy received US Food and Drug Administration (FDA) breakthrough designation last November​.

Alnylam holds the commercialisation rights to patisiran in the US, Canada and Western Europe, while Sanofi Genzyme aims to commercialise the product in the rest of the world.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us

Webinars

Headlines